Compositions of estrogen-cyclodextrin complexes

Details Compositions of estrogen-cyclodextrin complexes Compositions of estrogen-cyclodextrin complexes

2006-12-04

2009-08-04

Lewis, Patrick T (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S023000, C514S025000, C514S054000, C514S060000, C536S103000, C536S123100, C536S124000

Reexamination Certificate

active

07569557

ABSTRACT:
Pharmaceutical compositions comprising low doses of sensitive complexes between an estrogen and a cyclodextrin are provided with improved stability. In specific embodiments the composition comprises a complex between ethinyl estradiol and β-cyclodextrin in a granulate preparation and in yet another embodiment the composition comprises a limited amount of polyvinylpyrrolidone since this excipient was found to degrade ethinyl estradiol. Furthermore, a method for improving the stability of an estrogen in a composition and for manufacturing such a stable composition is provided. Essentially, the granulate preparation are manufactured under careful control of the relative humidity.

REFERENCES:
patent: 4129564 (1978-12-01), Wiechert et al.
patent: 4154820 (1979-05-01), Simoons
patent: 4383992 (1983-05-01), Lipari
patent: 4596795 (1986-06-01), Pitha
patent: 4727064 (1988-02-01), Pitha
patent: 4849425 (1989-07-01), Kondo et al.
patent: 4877774 (1989-10-01), Pitha et al.
patent: 4978532 (1990-12-01), El-Rashidy et al.
patent: 5324718 (1994-06-01), Loftsson
patent: 5376641 (1994-12-01), Ammeraal
patent: 5472954 (1995-12-01), Loftsson
patent: 5798338 (1998-08-01), Backensfeld et al.
patent: 5885978 (1999-03-01), Yamada et al.
patent: 6228399 (2001-05-01), Parikh et al.
patent: 2016780 (2000-07-01), None
patent: 0 349 091 (1990-03-01), None
patent: 0 579 435 (1994-01-01), None
patent: 0398460 (1997-07-01), None
patent: 2515187 (1982-10-01), None
patent: 2109381 (1983-06-01), None
patent: 04275235 (1992-09-01), None
patent: WO 96/02277 (1996-02-01), None
patent: WO 96/09056 (1996-03-01), None
patent: WO 98/27929 (1998-07-01), None
patent: WO 00/21570 (1999-10-01), None
patent: WO 01/15701 (2001-03-01), None
Parsey, K.S. et al., Contraception, 61(2):105-111, 2000.
Huber, J. et al., Europ. J. Contracep. Reprod. Health Care: Off. J. Europ. Society Contracep., 5(1):25-34, 2000.
Rolf Krattenmacher, “Drospirenone: pharmacology and pharmacokinetics of a unique progestogen,”COntraception, vol. 2, No. 1, Jul. 2000, pp. 29-38.
P. Norman, “Drospirenone: Contraceptive, Hormone Replacement Therapy, Aldosterone Antagonist, Progestogen: 1, 2-Dihydrospirorenone, SH-470, ZK-30595,”Drugs of the Future, vol. 25, No. 12, Dec. 2000, pp. 1247-1256.
K. Uekama et al., “Inclusion Complexations of Steroid Hormones With Cyclodextrins in Water and in Solid Phase,”International Journal of Pharmaceutics, 10 (1982), pp. 1-15.
K. Králová et al., “Interactions of β-cyclodextrin with steroid compounds in aqueous solutions,”Pharmazie, 1989, vol. 44, No. 9, pp. 623-625.
W.A.J.J. Hermens, “Delivery of hormones: some new concepts,”Pharm. Weekbl. Sci. Ed., 1992, vol. 14, No. 4 A, pp. 253-257.
K. Uekama, “Cyclodextrin Inclusion Compounds: Effects on Stability and Bio-Pharmaceutical Properties,”Topics in Pharmaceutical Sciences, Eds. D.D. Breimer and P. Speiser, 1987, Elsevier Science Publishers (Biomedical Division), pp. 181-194.
K. Uekama et al., “Cyclodextrin Drug Carrier Systems,”Chem. Rev., vol. 98, No. 5, Jul. 1, 1998, pp. 2045-2076.
Pitha et al., “Hydroxypropyl-β-cyclodextrin: preparation and characterization: effects on solubility of drugs,”International Journal of Pharmaceutics, 29(1), pp. 73-82 (1986).
European Search Report, Jun. 14, 2001.
Hafrun Fridriksdottir, design andin vivo testing of 17B-estradiol-HPBCD sublingual tablets, Die Pharmazie, Jan. 1996, pp. 39-42, No. 1, Eschborn, DE.
Thorsteinn Loftsson, The effect of water-soluble polymers on drug-cyclodextrin complexation, International Journal of Pharmaceutics, 1994, vol. 110, pp. 169-177.
Aultoun, M.E. (ed), Pharmaceutics : The Science of Dosage Form Design, P. York, The design of dosage forms, pp. 1-13, Churchill Livingstone, 1998.

Affiliated with

Also associated with

Rating

Compositions of estrogen-cyclodextrin complexes does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions of estrogen-cyclodextrin complexes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions of estrogen-cyclodextrin complexes will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4058689